The Washington Times: Biotech should take a page from Elon Musk’s playbookThe Washington Post:

04/08/2025

Innovation has always been the foundation of progress, but how we innovate matters as much as the results we achieve.

Recent breakthroughs in aerospace and artificial intelligence prove that massive budgets don’t drive innovation, but efficiency, speed and a relentless commitment to doing more with less do. Success comes from embracing resourcefulness as a strategic advantage, fueled by deep passion and bold thinking. Yet, the biotech industry has been slow to adopt this mindset. It’s time to rethink how we innovate in this field, prioritizing agility, smart investment and transformative ideas over outdated, costly models.

CLICK HERE to read Dr. Gabi Hanna’s full column in The Washington Times.

READ MORE

06/04/2025

Lamassu Biotech’s dog treatment could lead to human pancreatitis breakthrough, backed by NIH funds

Lamassu Biotech, the North Carolina-based biopharmaceutical company that opened a Cleveland office last year, has received a $2.7 million grant from the National Institutes of Health to help develop its therapy for dogs with acute pancreatitis. The therapeutic, called RABI-767, also could...

11/05/2024

Cleveland.com: Biotech startup Lamassu, Cleveland Clinic aim to treat rare cancers with just three pills a month

CLEVELAND, Ohio — A biotech startup from North Carolina thinks Cleveland is where it will develop how to treat rare cancers with just three pills a month. If effective, Lamassu Biotech’s innovative gene therapy could eliminate the need for surgery or chemotherapy...

09/23/2024

RealClear Health: Harris, Trump Must Tackle the Root Causes of High Drug PricesRealClear Health:

One of the most urgent challenges facing the American healthcare system is the complex and multifaceted issue of drug pricing. Like addressing a chronic disease, where treatment must go beyond alleviating symptoms to targeting the underlying cause, drug pricing reform...